Valuation: ABVC BioPharma, Inc.

Market Cap 2.7Cr 2.42Cr 2.23Cr 2.02Cr 3.78Cr 257.14Cr 3.84Cr 27Cr 11Cr 134.57Cr 10Cr 9.92Cr 426.23Cr P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 2.97Cr 2.66Cr 2.46Cr 2.22Cr 4.16Cr 283.11Cr 4.22Cr 29Cr 12Cr 148.17Cr 11Cr 11Cr 469.28Cr EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.73%
Yield 2024 *
-
Yield 2025 -
1 day-4.59%
1 week-0.70%
Current month-1.89%
3 months+2.97%
6 months+0.97%
Current year-51.17%
1 week 1.03
Extreme 1.03
1.11
1 month 0.89
Extreme 0.8918
1.11
Current year 0.71
Extreme 0.7069
2.43
1 year 0.71
Extreme 0.7069
3.06
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 21/06/2023
Chief Tech/Sci/R&D Officer 72 15/06/2023
Director TitleAgeSince
Director/Board Member 61 10/07/2022
Director/Board Member 70 -
Chairman 39 01/07/2015
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/22 Other

Chairman

79,08,805 26.0954%
02/08/21 Other

Director

5,949 0.0243%
02/08/21 Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
-4.59%-0.70%-62.45%-24.64% 2.7Cr
+0.34%+1.12%+34.75%+61.06% 6.44TCr
-0.12%+2.71%+14.38%+83.68% 5.62TCr
+1.11%+2.47%+15.94%+107.83% 5.42TCr
-1.43%-1.17%+26.27%+52.86% 4.53TCr
-0.48%-2.80%+18.01%+117.99% 4.22TCr
+0.82%+1.37%+227.94%+922.41% 4.08TCr
+0.45%+42.62%+105.00%+89.40% 3.38TCr
-0.26%-2.57%+12.55%+45.18% 3.22TCr
-1.69%-3.28%+21.10%-12.28% 2.36TCr
Average -0.59%+3.98%+41.35%+144.35% 3.93TCr
Weighted average by Cap. -0.04%+3.60%+49.92%+162.10%

Financials

2024 2025
Net sales 5L 5L 4L 4L 7L 4.85Cr 7L 50.24L 20.04L 2.54Cr 19.12L 18.72L 8.04Cr -
Net income -49.03L -43.92L -40.51L -36.66L -68.56L -47Cr -69.66L -4.83Cr -1.93Cr -24Cr -1.84Cr -1.8Cr -77Cr -79.09L -70.84L -65.35L -59.14L -1.11Cr -75Cr -1.12Cr -7.8Cr -3.11Cr -39Cr -2.97Cr -2.9Cr -124.83Cr
Net Debt 28.82L 25.81L 23.82L 21.55L 40.3L 27Cr 40.95L 2.84Cr 1.13Cr 14Cr 1.08Cr 1.06Cr 45Cr 27.27L 24.43L 22.54L 20.39L 38.14L 26Cr 38.75L 2.69Cr 1.07Cr 14Cr 1.02Cr 1Cr 43Cr
Projected Income Statement - Annual - ABVC BioPharma, Inc.
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
29/26/29 $1.040 -4.59% 34,879
28/26/28 $1.090 +3.81% 35,408
27/26/27 $1.050 0.00% 24,225
26/26/26 $1.050 +0.96% 36,596
23/26/23 $1.040 -0.70% 22,011
  1. Stock Market
  2. Stocks
  3. ABVC Stock